Proof-of-concept study to evaluate the safety, tolerability and efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer Epsilogen, the global leader in the development of ...

The antibody – called MOv18 IgE – targets folate receptor alpha which is particularly overexpressed on ovarian tumour cells. The drug is a CRUK-sponsored phase 1 trial due to report results at ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that it has commenced a Phase Ib study evaluating MOv18 IgE in patients with ...